KMX
46
-2
NWL
57
-4
THC
61
-4
ILMN
57
-2
FAST
63
2
MAS
58
-4
WMT
56
-3
GD
50
-2
EXR
48
-3
HCA
48
-2
HBAN
57
-2
CMG
54
-16
V
58
2
XRX
24
-3
LNC
65
5
MTCH
37
-2
HUM
37
3
CINF
47
12
ES
53
2
EXPE
77
5
KMX
46
-2
NWL
57
-4
THC
61
-4
ILMN
57
-2
FAST
63
2
MAS
58
-4
WMT
56
-3
GD
50
-2
EXR
48
-3
HCA
48
-2
HBAN
57
-2
CMG
54
-16
V
58
2
XRX
24
-3
LNC
65
5
MTCH
37
-2
HUM
37
3
CINF
47
12
ES
53
2
EXPE
77
5
Financhill
Back

Stoke Therapeutics 10K Form

Sell
27

STOK
Stoke Therapeutics

Last Price:
12.40
Seasonality Move:
11.82%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive STOK News And Ratings

See the #1 stock for the next 7 days that we like better than STOK

STOK Financial Statistics

Sales & Book Value

Annual Sales: $8.78M
Cash Flow: $-17.52M
Price / Cash Flow: 0
Annual Sales: $4.64
Price / Book: 2.69

Profitability

EPS (TTM): -2.18000
Net Income (TTM): $-103.57M
Gross Margin: --
Return on Equity: -57.17%
Return on Assets: -41.83%

Stoke Therapeutics Earnings Forecast

Key Stoke Therapeutics Financial Ratios

  • The Research & Development expenses have been 936.57% of Revenue.
  • The Net Earning history of STOK is -1,192.47% of Total Revenues.
  • Per Share Earnings over the last 7 years have been positive in 2 years.

Stoke Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: STOK
CUSIP: 86150R
Website: stoketherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 6.67
Quick Ratio: 6.34

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

STOK Technical Analysis vs Fundamental Analysis

Sell
27
Stoke Therapeutics (STOK) is a Sell

Is Stoke Therapeutics a Buy or a Sell?